INCB160058 + Standard disease-directed therapy
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Neoplasms
Conditions
Myeloproliferative Neoplasms
Trial Timeline
Aug 8, 2024 → Oct 9, 2028
NCT ID
NCT06313593About INCB160058 + Standard disease-directed therapy
INCB160058 + Standard disease-directed therapy is a phase 1 stage product being developed by Incyte for Myeloproliferative Neoplasms. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06313593. Target conditions include Myeloproliferative Neoplasms.
What happened to similar drugs?
0 of 1 similar drugs in Myeloproliferative Neoplasms were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
6
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06313593 | Phase 1 | Recruiting |
Competing Products
20 competing products in Myeloproliferative Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 29 |
| LY2784544 | Eli Lilly | Phase 1 | 29 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| AUY922 | Novartis | Phase 2 | 27 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 42 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 39 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 29 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 21 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 21 |
| Ruxolitinib | Incyte | Phase 2 | 32 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 24 |
| INCA036978 + Standard disease-directed therapy | Incyte | Phase 1 | 33 |
| Ruxolitinib | Incyte | Phase 2 | 24 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 24 |
| Ruxolitinib + Lenalidomide + Prednisone | Incyte | Phase 2 | 32 |
| itacitinib | Incyte | Phase 2 | 32 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 37 |
| Pemigatinib | Incyte | Phase 2 | 32 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 32 |
| INCA035784 | Incyte | Phase 1 | 33 |